Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Remuneration Information 2018

Dec 20, 2018

5262_dirs_2018-12-20_45ada5af-e6cc-44c9-816f-1c22e0f8f5c7.html

Remuneration Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1926L

GlaxoSmithKline PLC

20 December 2018

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Pharma Supply Chain
c) Initial notification/

amendment
Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a) Description of the financial  instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882
b) Nature of the transaction Cash payout of £47,832.11 less applicable tax withholding in respect of 3,231.899 notional Ordinary Shares following vesting of an award made on 16 December 2013 under the GlaxoSmithKline Deferred Investment Award plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£14.8000 3231.899
d) Aggregated information n/a (single transaction)
Aggregated volume Price
e) Date of the transaction 2018-12-17
f) Place of the transaction n/a

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHDBLFLVLFFFBZ